Abstract 101P
Background
Immunotherapy has achieved breakthrough progress in non-small-cell lung cancer (NSCLC), with some patients experiencing long-term benefits. However, reliable tools for predicting the risk of disease progression (PD) in these patients are lacking. Circulating tumor DNA minimal residual disease (ctDNA MRD) has demonstrated predictive values in early-stage and locally advanced NSCLC, but its role in advanced NSCLC remains unclear.
Methods
The CR1STAL study (NCT05198154) is a multicenter prospective cohort study utilizing ctDNA MRD to monitor the risk of PD in advanced NSCLC. Patients with stage IIIB-IV NSCLC receiving first-line immunotherapy who had progression-free survival of 1 year were screened. Peripheral blood samples were collected every 2-3 months, synchronized with radiographic efficacy evaluations. The personalized target-capture panels for ctDNA detection were tailored based on individual tumor variants identified through the ultra-depth sequencing of a 1021-gene panel. A plasma sample with at least one detected variant was defined as ctDNA MRD positive.
Results
30 NSCLC patients were included, with a median age of 63.5 years. 86.7% were male with median follow-up time of 30.2 months (95% CI 28.4 to 32.0 months). Patients underwent ctDNA MRD monitoring with a median frequency of 4 assessments (range: 3 to 8). 50% of patients tested positive of ctDNA MRD. Compare with the negative group, the ctDNA MRD positive group exhibited an increased risk of PD (hazard ratio: 20.73, 95% CI 2.67 to 161.08, p=0.004), offering a median lead time of 6.2 months (95% CI 5.4 to 7.8 months) than radiographic progression. Furthermore, among the 13 patients who experienced PD, 12 were detected as ctDNA MRD positive, demonstrating a sensitivity of 92.3% and a positive predictive value of 80%. Among the 17 patients with non-PD, 14 were confirmed as ctDNA MRD negative, exhibiting a specificity of 82.4% and negative predictive value of 93.3%.
Conclusions
ctDNA MRD emerges a promising biomarker to predict the risk of PD in advanced NSCLC patients with long-term response to immunotherapy. The surveillance of ctDNA MRD enables earlier detection of PD and facilitates prompt intervention in high-risk patients.
Clinical trial identification
NCT05198154: ctDNA Analysis to Monitor the Risk of Progression after First-line lmmunotherapy in Patients with Advanced NSCLC (CR1STAL).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07